Shares of Insperity (NSP), a human resources and business solutions provider, plunged 30.49% in pre-market trading on Tuesday following the release of disappointing third-quarter 2025 financial results and lowered full-year guidance. The company's performance fell significantly short of analysts' expectations, raising concerns about its profitability and future outlook.

Insperity reported a Q3 adjusted loss of $0.20 per share, a stark contrast to the $0.22 per share profit analysts had forecasted and a significant drop from the $0.39 per share earned in the same period last year. The company also posted an operating loss of $25 million, compared to the expected operating income of $3.44 million. Revenue for the quarter rose 4% to $1.62 billion, slightly below the $1.63 billion analysts anticipated.

The poor performance was primarily attributed to elevated healthcare costs, including inpatient, outpatient, and pharmacy trends, which negatively impacted gross profit. In response to these challenges, Insperity announced a multi-year contract extension with UnitedHealthcare, expected to provide significant cost reductions starting in 2026. However, this did little to assuage investor concerns in the near term. The company has trimmed its full-year 2025 adjusted EPS guidance to a range of $0.84 to $1.47, well below the previous Wall Street consensus of $2.11. Adding to the negative sentiment, JP Morgan cut its price target for Insperity from $51 to $34, reflecting reduced confidence in the company's near-term prospects.